Lp(a): The Heart Risk Hiding in 1 in 5 Adults

A man in his late forties sat across from me last month and slid a printed PDF across the desk. It was his annual health screening report. His LDL cholesterol was 2.6 mmol/L. Blood pressure 122 over 78. Fasting glucose normal. HbA1c normal. BMI 23. He runs five kilometres three times a week and has never smoked. By every standard line on the page, he was a model patient. "So my heart is fine, right?" he said. Then he paused. "It's just that my father had a heart attack at fifty-two. And his brother had a stroke at fifty-five. Both ran. Both ate well. So I keep wondering what they were missing."

He had come because of a TikTok video. The video was about a blood test almost no Singaporean has heard of. It is not on his annual screening panel. It is not on most insurance check-ups. And in March 2026 the American College of Cardiology and the American Heart Association, in the most significant lipid guideline update in eight years, said for the first time that every adult should have this test done at least once in their life. The test is for lipoprotein(a), pronounced lipoprotein little-a and written Lp(a). And the man across my desk had every reason to be asking.

This is the story of Lp(a), why a major guideline just made it a Class I recommendation, why it is especially relevant for some Singaporean families, and what it actually changes in clinical practice today. The honest read includes a real limitation: we still cannot meaningfully lower Lp(a) with current first-line treatments. So why test for it at all? That answer turns out to be more interesting than it first appears.

What Lp(a) Actually Is

To understand Lp(a) you need to know about LDL, its better-known cousin. LDL, low-density lipoprotein, is the particle that carries cholesterol through the bloodstream and the one that deposits it into artery walls when in excess. It is the central character in the heart disease story most patients have heard.

Lp(a) is, structurally, an LDL particle with an extra component bolted on. Attached to its main apolipoprotein B-100 backbone is a second protein called apolipoprotein(a), the so-called "little a", linked by a single disulphide bond. This little-a tail is the troublemaker. It is genetically variable in size, and that variation, controlled by the LPA gene on chromosome 6, is the single biggest determinant of how much Lp(a) someone has in their blood. Diet barely moves it. Exercise barely moves it. Statins, the workhorse of cholesterol management, also barely move it (and in some studies actually raise it modestly). What you inherit from your parents is essentially what you carry for life. Levels rise a little after menopause and in chronic kidney disease, but otherwise your Lp(a) at age 25 is a reasonable estimate of your Lp(a) at age 75.

The little-a tail also looks structurally similar to plasminogen, a protein your body uses to break down blood clots. That structural mimicry is one of the mechanisms by which Lp(a) is thought to be more atherogenic than LDL: it not only deposits cholesterol but may also interfere with the body's natural clot-dissolving machinery. Lp(a) particles also carry pro-inflammatory oxidised phospholipids on their surface, adding a second inflammatory hit to the artery wall.

About one in five adults globally, an estimated 1.4 billion people, carries an Lp(a) level above the threshold now considered elevated. Most of them do not know it. And until very recently, neither did most of their doctors.

Why the Evidence Got Strong Enough to Change a Guideline

For decades, Lp(a) was considered a curiosity. We knew higher levels tracked with more heart attacks in observational studies, but observational data is plagued by confounding. Maybe the people with high Lp(a) also smoked more, exercised less, ate worse. The skeptics had a point.

What changed everything was Mendelian randomization. This is a clever statistical method that uses naturally occurring genetic variants as the equivalent of a randomised trial. Because LPA gene variants are inherited at birth, randomly and independently of lifestyle factors, comparing people who genetically inherit high Lp(a) against those who inherit low Lp(a) is biologically similar to randomising them at birth. A landmark 2009 analysis by Kamstrup, Tybjaerg-Hansen and Nordestgaard, published in JAMA, pooled data from the Copenhagen General Population Study and the Copenhagen City Heart Study, with over 70,000 participants tracked for decades, and showed that genetically determined high Lp(a) was causally linked to myocardial infarction. Subsequent Mendelian randomization studies have replicated and extended this for stroke, peripheral vascular disease, heart failure, and aortic valve stenosis. The Mendelian randomization literature is now arguably the strongest non-RCT evidence we have for any cardiovascular risk factor, and it points one way: Lp(a) is not just associated with heart disease, it causes it.

The European Atherosclerosis Society 2022 consensus statement, led by Florian Kronenberg, was the first major society document to consolidate this evidence and recommend Lp(a) testing once in every adult's life. The 2025 ESC/EAS focused update kept that recommendation. The 2024 National Lipid Association statement aligned. The 2026 ACC/AHA Multisociety Dyslipidemia Guideline, published in Circulation on 13 March 2026, gave the recommendation its highest weight: a Class I recommendation for universal Lp(a) measurement, once, in all adults. This is the strongest tier of recommendation, reserved for interventions where the benefit clearly outweighs the risk. In the language of guideline committees, this is not a "consider it" recommendation. It is a "should do it" recommendation.

What the Numbers Mean

Lp(a) is measured in either nmol/L (the unit the new guidelines prefer, because it counts the number of particles directly) or mg/dL (the older mass-based unit). Both still appear on lab reports in Singapore, which is unhelpful and confusing.

The thresholds in the 2026 ACC/AHA guideline read roughly as follows. Below 75 nmol/L (approximately 30 mg/dL) is considered low and reassuring. Between 75 and 125 nmol/L sits in a borderline zone. Above 125 nmol/L (approximately 50 mg/dL) is elevated and is associated with about a 1.4-fold higher long-term risk of heart attack and stroke. Above 250 nmol/L (approximately 100 mg/dL) is high, with at least a two-fold increased long-term risk. A Singapore-based premature ischaemic heart disease cohort study found that an Lp(a) threshold around 155 nmol/L corresponded to a 2.9-fold increased risk of early-onset coronary artery disease in our local population.

Because the assays use different antibodies and report in different units, the same blood sample sent to two different laboratories can give different absolute numbers. This is improving as international standardisation rolls out, but it is worth knowing if you ever retest. Use the same laboratory and the same assay where possible.

The Singapore and Asian Angle

Lp(a) distribution varies substantially by ethnicity, and Singapore happens to be one of the few places on earth where that variation is documented directly within a single national population.

A landmark study by Low and colleagues published in Atherosclerosis in 1996 measured Lp(a) in cord blood from Singaporean newborns of Chinese, Malay, and Indian ethnicity. Indian newborns had the highest mean Lp(a) levels. Chinese newborns had the lowest. Malay newborns sat in between. Critically, the ranking of Lp(a) at birth mirrored adult coronary mortality rankings by the same three ethnic groups. The signal was visible before any baby had touched a chicken rice or smoked a cigarette.

Subsequent work in Singapore and across Asia has confirmed and extended this. A 2025 comprehensive review by Lim and Tay in the Journal of Lipid and Atherosclerosis mapped Lp(a) prevalence across Asian populations and found South Asians (including Indian-origin populations) carry meaningfully higher Lp(a) levels than East Asian populations, with intermediate levels in Southeast Asian groups including Malays. This is part of why the longstanding observation that Indian-origin populations have higher rates of premature coronary disease, controlling for traditional risk factors, never fully went away. Some of that residual risk is Lp(a).

This does not mean Chinese-Singaporeans should ignore the test. Plenty of Chinese-Singaporeans carry elevated Lp(a); the average is lower, but the spread of individual values within any ethnic group is wide. It does mean that if you are an Indian-origin Singaporean with a family history of premature heart disease, this is a conversation worth having sooner rather than later with your own doctor.

It is worth being honest about where Singapore's own guidelines currently sit. The Academy of Medicine of Singapore 2023 lipid management clinical practice guidelines, the most recent national framework, mention Lp(a) but do not yet make universal once-in-a-lifetime testing a formal recommendation. The 2025 Singapore Acute Coronary Syndrome guidelines acknowledge Lp(a) as an emerging risk modifier. A 2024 survey of Singapore specialists, published as "Deficient perceptions and practices concerning elevated lipoprotein(a) among specialists in Singapore", found that most local cardiologists, endocrinologists and primary care doctors did not routinely test for Lp(a). The international evidence base has moved faster than national guidance, and that is the gap the public conversation, including this article, is trying to fill responsibly.

So If You Find Out, What Changes?

This is the most legitimate question patients ask, and the most important one to answer honestly. If we cannot yet meaningfully lower Lp(a) with widely available therapy, what does the test actually buy you?

Three things, broadly.

First, the rest of your risk picture gets reweighted. A man with LDL of 2.6 mmol/L, blood pressure of 122/78, and no other classical risk factors might be told he is "low risk" by a standard cardiovascular calculator. Add an Lp(a) of 280 nmol/L into that picture and the calculation changes. The 2026 ACC/AHA guideline explicitly acknowledges that elevated Lp(a) is a risk-enhancing factor that justifies more aggressive management of every other modifiable risk variable. That means tighter LDL targets (often using more potent therapy, including non-statin agents like PCSK9 inhibitors, in patients who would not otherwise have qualified), more aggressive blood pressure control, stricter glucose targets, lower thresholds for further cardiovascular imaging such as coronary calcium scoring. You cannot bring Lp(a) down with current first-line therapy. But you can bring LDL much lower, smoke not at all, sleep more, and that is genuinely consequential.

Second, family cascade screening becomes possible. Lp(a) is inherited in an autosomal codominant pattern. If a parent has elevated Lp(a), each child has roughly a 50 per cent chance of inheriting an elevated level. A first-degree relative of an affected individual has a far higher pre-test probability than a random person in the population. The 2026 ACC/AHA guideline now formally endorses cascade screening of first-degree relatives when an index case is identified. For families with a history of premature coronary disease that has never been satisfactorily explained, this is the most actionable change the new guideline brings. Testing one person can change the medical pathway for an entire family branch.

Third, you are positioned for the therapies that are coming. Three classes of Lp(a)-specific drugs are in advanced trials. Olpasiran, a small interfering RNA from Amgen, showed in the OCEAN(a)-DOSE phase 2 trial published by O'Donoghue and colleagues in the New England Journal of Medicine in 2022 that doses of 75 mg or higher every 12 weeks reduced Lp(a) by more than 95 per cent, with effects sustained for months after the last dose. The phase 3 OCEAN(a) outcomes trial, which will tell us whether lowering Lp(a) actually reduces heart attacks and strokes, is expected to read out in 2027. Pelacarsen, an antisense oligonucleotide, is being studied in the parallel Lp(a)HORIZON trial. Muvalaplin, a first-in-class oral small molecule, has shown in early-stage trials it can reduce Lp(a) substantially without injections. All three lower the molecule dramatically. None of them has yet proved it lowers cardiovascular events. Until the outcomes trials read out, we cannot say with certainty that knocking Lp(a) down translates into fewer heart attacks. The biological plausibility is high. The clinical proof is pending.

The honest framing for patients is this. Testing Lp(a) today tells you about a genetic risk factor that you can act on indirectly, by optimising everything else, by screening your family, and by knowing your status if and when targeted therapy becomes available. It is not yet a test that comes with its own dedicated treatment. But the test is a one-off, inexpensive in the context of a lifetime of cardiovascular risk management, and the information does not expire.

What This Doesn't Mean

Three honest cautions, because the longevity content space has a habit of overselling.

Lp(a) is one risk factor among many. A normal Lp(a) does not make you bulletproof. Most heart attacks in Singapore are still driven by smoking, hypertension, diabetes, ApoB-containing lipoproteins (of which LDL is the largest component), poor sleep, sedentary lifestyle and visceral adiposity. If your Lp(a) is low and you smoke a pack a day, your risk is high. If your Lp(a) is high and you do not smoke, your blood pressure is 110/70, your LDL is 1.8 on therapy, and your VO2 max is at the 80th percentile for your age, your risk is meaningfully lower than the population average for high-Lp(a) people.

The currently available "Lp(a)-lowering" supplements and over-the-counter products are mostly not lowering Lp(a) by any clinically meaningful amount. Niacin (vitamin B3) at high doses can lower Lp(a) by around 20 to 30 per cent, but the AIM-HIGH and HPS2-THRIVE trials both showed that niacin added to statin therapy did not reduce cardiovascular events and carried real harms (worsening glycaemic control, gout, gastrointestinal side effects, and rare serious adverse events). Niacin is not used as Lp(a) therapy for that reason. Most "natural Lp(a) protocols" sold online are wishful thinking. Be skeptical of anything that promises to "lower your Lp(a) naturally". Discuss any consideration of high-dose niacin or other agents specifically with your own doctor; do not start it from a blog.

Aspirin has been discussed as a potential mitigant for high-Lp(a) individuals on the basis of the WHS (Women's Health Study) post-hoc analysis and the more recent ASPREE secondary analyses, but the evidence is observational and primary prevention aspirin use has shifted in recent years toward more selective use due to bleeding risk. Do not start aspirin on your own. Aspirin in primary prevention is now a nuanced individualised conversation with a doctor who knows your bleeding risk, not a blanket recommendation.

What He Went Home With

We tested. His Lp(a) came back at 278 nmol/L, in the upper-elevated range. He sat with that number for a few days. Then he came back to clinic. We did not panic. We did the things that were going to happen anyway, but with sharper edges. We tightened his LDL target. We doubled down on his sleep and his strength training, both of which were already decent but had drifted. We added a coronary artery calcium score, which came back zero, which was reassuring and slightly disorientating at the same time. (A high Lp(a) with a zero calcium score is a known clinical pattern: it means his arteries have not yet visibly calcified, which is encouraging, but it does not erase the lifetime genetic risk and we will recheck in five years.) We talked about his two brothers and his children. He went home and asked his brothers to get tested. Both did. One was elevated. One was not. The family map redrew itself in a single weekend.

His father, who died at fifty-two, was never tested. None of us know what his Lp(a) was. The point of this story is not that Lp(a) explained his death. The point is that for the next generation, the test exists, the evidence is now strong enough to justify a one-off measurement in every adult, and the decision a Singaporean patient and their doctor make today can shape the medical conversation in that family for the next thirty years.

This is something to discuss with your own doctor. Bring the question in. Ask whether an Lp(a) test makes sense for you given your family history, your ethnicity, and your other cardiovascular risk factors. Your doctor knows your full medical history, your medications, and your individual context. This article is a starting point for that conversation, not a substitute for it.

Dr Samuel Choudhury, MBBS (NUS) · MPH (Johns Hopkins) · GDFM · GDFP Derm

References

1. Writing Committee. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. Published online 13 March 2026. doi:10.1161/CIR.0000000000001423
2. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal. 2022;43(39):3925-3946. doi:10.1093/eurheartj/ehac361
3. Kronenberg F, Mora S, Stroes ESG, et al. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society. Atherosclerosis. 2023;374:107-120. doi:10.1016/j.atherosclerosis.2023.03.012
4. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331-2339. doi:10.1001/jama.2009.801
5. O'Donoghue ML, Rosenson RS, Gencer B, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease (OCEAN(a)-DOSE). New England Journal of Medicine. 2022;387(20):1855-1864. doi:10.1056/NEJMoa2211023
6. Lim YC, Tay JC. Lipoprotein(a) and cardiovascular risk in Asian populations: a comprehensive review. Journal of Lipid and Atherosclerosis. 2025;14(2):174-191. doi:10.12997/jla.2025.14.2.174
7. Low PS, Heng CK, Saha N, Tay JS. Racial variation of cord plasma lipoprotein(a) levels in relation to coronary risk level: a study in three ethnic groups in Singapore. Atherosclerosis. 1996;124(2):247-255. PubMed PMID: 8910937
8. Chua YC, Loh PH, Foo R, et al. Deficient perceptions and practices concerning elevated lipoprotein(a) among specialists in Singapore. Singapore Medical Journal / Annals Academy of Medicine Singapore (open-access PMC). 2024. PMC ID: PMC11868285
9. Academy of Medicine, Singapore. Clinical Practice Guidelines: Lipid Management 2023. Available at: ams.edu.sg
10. Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 2022;42(1):e48-e60. doi:10.1161/ATV.0000000000000147